Cochlear Limited (ASX:COH)
Australia flag Australia · Delayed Price · Currency is AUD
93.52
-2.81 (-2.92%)
May 18, 2026, 4:10 PM AEST

Cochlear Earnings Call Transcripts

Fiscal Year 2026

  • Trading update

    Lower sales and profit are driven by weak demand in developed markets, Middle East disruptions, and China reimbursement changes. Strategic focus remains on medicalizing hearing loss and accelerating growth initiatives, with a wide guidance range reflecting ongoing uncertainty.

  • First half results were impacted by the Nexa launch, leading to a 2% revenue decline and 17% net profit margin, with strong second half growth expected. FX headwinds and competitive pressures affected margins and share, but restructuring and growth initiatives are underway.

Fiscal Year 2025

  • AGM 2025

    The AGM reviewed solid financial results, with sales and profit growth, increased dividends, and strong R&D investment. Board renewal, global expansion, and sustainability were emphasized, while shareholders raised questions on strategy, competition, and market risks.

  • Revenue grew 4% year-over-year with strong Cochlear implant and emerging market growth, but services declined 10% due to U.S. consumer hesitancy and a smaller eligible base. The Nexa system launch and continued R&D investment support a positive outlook, though China pricing and U.S. uncertainty remain headwinds.

  • Net sales rose 6% with strong implant and acoustics growth, but services revenue declined due to U.S. cost pressures. Guidance is maintained at the lower end, with increased cloud investment and a major new product launch expected mid-year.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Powered by